Skip to Content
Merck
CN
  • Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.

Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.

Carcinogenesis (2019-06-07)
Amrendra Mishra, Fatemeh Emamgholi, Zulrahman Erlangga, Björn Hartleben, Kristian Unger, Katharina Wolff, Ulrike Teichmann, Michael Kessel, Norman Woller, Florian Kühnel, Lukas E Dow, Michael P Manns, Arndt Vogel, Scott W Lowe, Anna Saborowski, Michael Saborowski
ABSTRACT

Beyond the nearly uniform presence of KRAS mutations, pancreatic cancer is increasingly recognized as a heterogeneous disease. Preclinical in vivo model systems exist, but with the advent of precision oncology, murine models with enhanced genetic flexibility are needed to functionally annotate genetic alterations found in the human malignancy. Here, we describe the generation of focal gene disruptions and large chromosomal deletions via inducible and pancreas-specific expression of Cas9 in adult mice. Experimental mice are derived on demand directly from genetically engineered embryonic stem cells, without the need for further intercrossing. To provide initial validation of our approach, we show that disruption of the E3 ubiquitin ligase Rnf43 accelerates KrasG12D-dependent tumourigenesis. Moreover, we demonstrate that this system can be used to rapidly interrogate the impact of complex cancer-associated alleles through the generation of a previously unstudied 1.2 megabase deletion surrounding the CDKN2A and CDKN2B tumour suppressors. Thus, our approach is capable of reproducibly generating biallelic and precise loss of large chromosomal fragments that, in conjunction with mutant Kras, leads to development of pancreatic ductal adenocarcinoma with full penetrance.

MATERIALS
Product Number
Brand
Product Description

Millipore
Microcon® Centrifugal Filters, NMWCO 30 kDa, Ultracel® regenerated cellulose membrane (low binding), sample volume 0.5 mL
Sigma-Aldrich
Collagenase from Clostridium histolyticum, suitable for release of physiologically active rat hepatocytes, Type IV, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
Deoxyribonuclease I from bovine pancreas, lyophilized powder, Protein ≥85 %, ≥400 Kunitz units/mg protein
Sigma-Aldrich
ESGRO® Recombinant Mouse LIF Protein, ESGRO Leukemia Inhibitory Factor (LIF) supplement for mouse ES cell culture. Each vial contains 10^7 units/ml.